FDA leaders have announced a change in how they intend to approach the evidence needed to demonstrate a drug’s effectiveness. That announcement deserves attention from manufacturing and quality teams, but it does not set an 18-month deadline or remove product-specific review.

On February 18, 2026, FDA Commissioner Martin Makary and CBER Director Vinay Prasad published a commentary in the New England Journal of Medicine announcing a policy direction: one robust pivotal trial plus confirmatory evidence would be the default approach, rather than two trials. That is a policy announcement by agency leaders, not a new statute or a promise that any particular application will be approved after one trial.

My operational concern is narrower. If a sponsor’s development plan changes, its manufacturing-readiness plan may need to change with it. The timing and evidence needed for each program still depend on the product, the development data, and FDA feedback.

What Actually Changed

Federal law has allowed FDA to find substantial evidence of effectiveness from one adequate and well-controlled investigation plus confirmatory evidence when the agency determines that evidence is sufficient. The 1997 statutory amendment clarified that option. It did not impose a universal two-trial rule that had to be repealed in 2026.

The February 2026 commentary announced a change in FDA leaders’ default policy posture. FDA’s June 2026 revised draft guidance, issued after this newsletter’s original publication, describes circumstances in which one investigation plus confirmatory evidence may satisfy the substantial-evidence standard. The guidance is a draft, is not for implementation, and contains nonbinding recommendations. A sponsor still needs an evidence plan appropriate to its product.

Neither source establishes a universal reduction in development time. The announcement does not require every sponsor to conduct only one pivotal trial, shift missing evidence automatically to postmarket surveillance, or guarantee a faster approval.

What This Could Mean for Manufacturing

If a specific program can support its application with one pivotal trial and confirmatory evidence, its manufacturing team should revisit assumptions about when it will have representative process data, qualified personnel, supplier evidence, and a commercial-quality system. That is planning advice, not a new FDA deadline.

For a cell or gene therapy program, the number of available manufacturing runs may already be limited. A change in clinical study design could affect the opportunities to observe process variability and train operators. It does not by itself change FDA’s applicable CMC or CGMP expectations. Sponsors should discuss program-specific evidence and timing with their regulatory, quality, clinical, and manufacturing teams.

Process and Equipment Qualification

Review whether the available runs and planned studies will support the process and equipment qualification strategy. FDA’s 2011 process validation guidance describes a lifecycle approach to demonstrating that a process performs as intended. The appropriate evidence is specific to the process and product; one clinical-trial design does not settle it.

Operator and Supplier Readiness

Map the tasks that operators and reviewers must perform, define qualification evidence, and plan trainer capacity. Review critical raw-material suppliers and the information needed to support their qualification. These are useful steps whether the clinical program has one pivotal trial or more.

PreCheck Is a Separate, Voluntary Pilot

FDA began accepting requests for its PreCheck Pilot Program on February 1, 2026. The pilot concerns early engagement about certain new U.S. manufacturing facilities. Participation is voluntary, eligibility is limited, and FDA states that selection does not guarantee expedited product review, approval, or inspection outcomes. It is not part of the one-trial evidentiary standard.

For an eligible organization, earlier facility discussions may help surface questions sooner. Other sponsors can still plan manufacturing readiness early and use the ordinary FDA interaction pathways appropriate to their programs.

Five Practical Reviews

1. Reconcile the development and manufacturing plans. Identify which clinical and manufacturing data are expected before the application and which assumptions depend on an additional trial.

2. Review process qualification evidence. Confirm that the planned studies and manufacturing runs support the process and product, and identify any gaps for discussion with FDA.

3. Define operator readiness. Build role-based training, task qualification, and documented evidence for the work personnel will actually perform.

4. Review supplier and quality-system capacity. Plan critical-material qualification, deviation handling, and change control before commercial demand arrives.

5. Revisit the plan as evidence develops. Track assumptions, responsible owners, decision points, and FDA feedback. A policy direction should prompt a review, not a calendar shortcut.

The Bottom Line

FDA leaders announced a one-pivotal-trial default with confirmatory evidence, while the statutory standard of substantial evidence remains. Whether a particular program can use that route, and what it means for its schedule, must be determined case by case.

My recommendation is to connect clinical planning with manufacturing, quality, supplier, and workforce readiness now. That work is valuable regardless of the number of pivotal trials. It does not replace product-specific regulatory advice or establish an 18-month clock.

References

  1. Prasad V, Makary MA. One pivotal trial, the new default option for FDA approval. N Engl J Med. Published online February 18, 2026. Policy announcement.
  2. FDA. One investigation and confirmatory evidence. September 2023 draft guidance. Existing legal framework.
  3. FDA. Demonstrating Substantial Evidence of Effectiveness. June 2026 revised draft guidance. Published after this issue’s original date.
  4. FDA. PreCheck Pilot Program. Voluntary program for eligible new U.S. facilities.
  5. FDA. Process Validation: General Principles and Practices. January 2011.

That’s it for Issue #3. If this was useful, forward it to someone on your quality team. If you want to talk about any of this in more detail, I’m at bdrapeau@gxpframe.com.

Brian Drapeau
Founder, GxP Frame
gxpframe.com

See you next week!